Failure to recognize interferon-associated pulmonary toxicity may result in persistence of pulmonary damage. Mortality was seen only in patients treated with pegylated interferon combination therapy. Therefore, clinicians should be aware of development of interstitial pneumonitis in chronic hepatitis C patients who develop pulmonary symptoms such as cough or dyspnea. The threshold for obtaining chest X-ray or pulmonary HRCT scan in these patients should be low.